Translational value of mouse models in oncology drug development.
about
Engineered Swine Models of CancerRho, ROCK and actomyosin contractility in metastasis as drug targetsStromal Targets for Fluorescent-Guided Oncologic SurgeryTumor-Derived Cell Lines as Molecular Models of Cancer PharmacogenomicsDrug Discovery via Human-Derived Stem Cell OrganoidsToward understanding and exploiting tumor heterogeneitySmall-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse ChemotherapeuticsEfficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical DataEfficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent ModelsIn vitro experimental models of mesothelioma revisitedInsider information: Testing cancer drug sensitivity for personalized therapyInoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine ModelTargeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Precision Oncology Framework for Investigation of Exercise As Treatment for Cancer.A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.Targeting and Regulating of an Oncogene via Nanovector Delivery of MicroRNA using Patient-Derived Xenografts.Lung cancer nanomedicine: potentials and pitfalls.Challenges in the design of reliable immuno-oncology mouse models to inform drug development.Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer.Genetically engineered mouse models of craniopharyngioma: an opportunity for therapy development and understanding of tumor biology.Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.Autologous reconstitution of human cancer and immune system in vivo.Patient-derived induced pluripotent stem cells in cancer research and precision oncology.Targeting metastasis.Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM).One microenvironment does not fit all: heterogeneity beyond cancer cells.The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform.Tumor location impacts immune response in mouse models of colon cancer.Zebrafish Xenograft: An Evolutionary Experiment in Tumour Biology.Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening.Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments.Preclinical Optimization of Antibody-based Radiopharmaceuticals for Cancer Imaging and Radionuclide Therapy - Model, Vector, and Radionuclide Selection.Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.In silico cancer research towards 3R.Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.
P2860
Q26744575-5BC9EAE9-B062-4E8C-9AE5-91649B0C72CDQ26751189-A132737E-CEFC-4E3F-A1D7-FD86029A88FBQ26774497-AE02051B-FC08-49FA-8BD0-03B3FAFBC028Q26801410-B4FD3BBF-D03A-41C3-84D2-28F5A236430AQ28066424-53BF5C2D-3DC5-4DA9-BA30-2CE4C73EA894Q28603034-8FAF0199-D2CB-4162-9ADA-290C064D217EQ29027136-71390456-2810-400F-BDDB-16A4EE463385Q31112729-277BA445-621D-4BD1-B616-14E104C9E5FDQ33740334-E5BD9739-2DF6-4F22-9C49-AE2310618DB4Q33890506-B64D2B5A-DBB4-4B2E-B51A-A9CBBC0AB93BQ36175238-EDC12CCA-C951-43D8-A2BA-60E4DFD003F5Q36184480-72EE82F2-83F5-4A81-A1C8-B927F227CA04Q36192485-6718E4C0-0150-4C81-9B8E-D2170BCD2C37Q36301061-5BC8A0CB-7CB7-42BC-8683-3C5F81721F5BQ37163870-BC5CBF74-26AE-49BB-86F5-60A1B99AF9E3Q37645045-58F69497-600C-400E-9534-2F50F97ACE65Q37668563-08430C76-9029-4ACB-9365-72C979EE25BDQ38608622-8A48A5CE-CEF8-4B7F-BACA-A1348F08639EQ38647681-DEC69A28-7CCB-4187-87F9-2AE8255E63A9Q38697671-F3BEBAB8-43F3-46AD-823F-85CF06174B65Q38729611-74E36681-DF17-40F0-ABFE-71879CA94008Q38753542-70BCFC07-9899-4850-A868-92B6E0F89EA0Q38779010-49732F22-FA4B-48AC-A608-31FBC85A1B88Q38786566-7740FABE-1423-4D16-9732-33022ADE46E3Q38786658-F9EA7BF7-DA0B-4C13-B290-7E9113AC36C6Q38795629-038A4700-9AED-418B-98BB-104CB8461548Q38822873-ADBA193E-4AAA-4B6E-918E-DFB6FC1C9363Q38834695-00DC0208-0BCA-405E-9913-1A4027763DADQ39011826-60485AA9-9336-4B83-8D25-0E331B2EFE66Q41526718-1E6EF50F-0216-4459-9CA9-11A9702B8EEDQ41550721-A56453C3-FA40-400C-9865-23B648113F28Q41673632-9881E990-35A7-47BA-8F5F-E85571E10C34Q46914962-EFA1D50C-1C47-4530-B992-C9FFE44AFF90Q47566445-639470B7-80D9-4B44-9F84-4CCC1F254E94Q47791066-7D6B1D2E-B379-44FC-9FD7-413F43375D2EQ48089417-9E52C72C-06E9-4827-A9F7-20D7B22F850EQ49832498-0638121F-4A81-4B95-B436-1EC908779FC8Q52313265-4A16B3C0-C3DD-4A7A-8927-A6C92FCAAECBQ52323287-F5DE35B9-C887-4889-AE77-C3556FA7052AQ53037025-0C33CED2-39A9-4A2A-B707-846223D8CEC2
P2860
Translational value of mouse models in oncology drug development.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Translational value of mouse models in oncology drug development.
@en
type
label
Translational value of mouse models in oncology drug development.
@en
prefLabel
Translational value of mouse models in oncology drug development.
@en
P2860
P356
P1433
P1476
Translational value of mouse models in oncology drug development.
@en
P2093
Frederic J de Sauvage
Melissa R Junttila
P2860
P2888
P304
P356
10.1038/NM.3853
P407
P577
2015-05-01T00:00:00Z